Dashboard

Financial News

globenewswire_fr49d ago

Applied Digital Announces $300 Million Senior Secured Bridge Facility

DALLAS, May 04, 2026 (GLOBE NEWSWIRE) -- Applied Digital Corporation (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads, today announced the closing of a $300 million senior secured bridge facility led by Goldman Sachs.

#CRYPTO
eBay Confirms Receipt of Unsolicited Proposal from GameStop
cision49d ago

eBay Confirms Receipt of Unsolicited Proposal from GameStop

No Action Required from eBay Shareholders at This Time SAN JOSE, Calif., May 4, 2026 /PRNewswire/ -- eBay Inc. (Nasdaq: EBAY), a global commerce leader that connects millions of buyers and sellers around the world, today confirmed that it has received an unsolicited, non-binding...

#STOCKS
financialcontent49d ago

Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics

Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, on May 1, 2026, Assertio and Garda Therapeutics (“Garda”) entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Garda has increased its offer to acquire all outstanding shares of Assertio to $21.80 per share in cash with no contingent value right.

#STOCKS
Sun Life Global Investments Expands Granite Target Date Solutions to Meet Evolving Needs of Canadian Employers
benzinga49d ago

Sun Life Global Investments Expands Granite Target Date Solutions to Meet Evolving Needs of Canadian Employers

Expanded suite designed to support the savings goals and retirement readiness of Canadian employees TORONTO , May 4, 2026 /CNW/ - Today, SLGI Asset Management Inc. ("Sun Life Global Investments") announced the expansion of its Granite solutions with Sun Life Granite Index+ Target Date Funds (Granite Index+). As the largest Canadian-based target date fund manager, 1 Sun Life Global Investments is responding to the growing demand for more differentiated target date funds that support long‐term retirement outcomes for Canadian plan members. Sun Life Granite Target Date Funds, a flagship retirement solution for more than 15 years, were built for Canadian employers who want a highly diversified solution and believe active management adds value over time. As Canadians' financial needs have evolved, Granite Index+ was introduced to offer another choice: a simpler, predominantly passive option that still provides broad diversification and access to private markets, at a competitive fee. Together, the Granite lineup gives employers more flexibility to choose a default solution that fits their plan's goals, governance model and fee budgets. "We're seeing the needs and preferences of Canadian employers evolve, and we're focused on creating solutions that meet them where they are," said Anne Meloche, Head of Institutional Business, Sun Life Global Investments. "With target date funds serving as the default choice for 81% of workplace plans, 2 it's critical that companies have options that align with their investment preferences, fee budget and fiduciary responsibilities to better support their members being retirement ready." Redefining the retirement landscape with resilient portfolios Granite Index+ is managed by the Canadian-based ... Full story available on Benzinga.com

#STOCKS
Independent's Senior Expo is this morning in Sun City
yourvalley_net49d ago

Independent's Senior Expo is this morning in Sun City

The Sun City Independent's Senior Expo will return 9 a.m.-noon Monday, May 4, at the Sundial Recreation Center, 14801 N. 103rd Ave. There will be an extensive selection of products and ...

#COMMODITIES
globenewswire_fr49d ago

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

SALT LAKE CITY, May 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced receipt of final meeting minutes following its recent Type C meeting with the U.S. Food and Drug Administration (FDA).

#COMMODITIES